Skip to main content
OpenTrials
Completed

NCT Number: NCT03534752

Retrospective Study of Adult Patients With Inborn Errors of Metabolism in Switzerland

This is a retrospective study aimed at establishing a database of the current health of adult patients with IEM in the French-speaking part of Switzerland. .

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Lausanne University Hospitals

Lausanne, Canton of Vaud, 1011, Switzerland

About this study

Background Inborn errors of metabolism (IEMs) are a group of rare disorders caused by genetic mutations that affect enzymes of intermediary metabolism. Because adult with IEMs has become an emerging and challenging group in Switzerland, this study is intended to assess the actual situation of adult patients with IEM in the French-speaking part of Switzerland, namely their age, their sex, their diagnosis, age at disease onset and their clinical outcome including complications of the disease.

All adult patients with a biochemical and/or genetic diagnosis of IEM followed at the adult metabolic clinic from the Lausanne University Hospital and Geneva University Hospital between 01.10.2013 to 31.12.2017 will be included in the study. In addition, investigators will also include the patients referred to the clinic for suspicion of IEM and determinate if the investigation confirmed an IEM disease. Electronic and paper patient charts will be reviewed for clinical features, biochemical investigations, molecular genetic testing, diagnostic imaging, treatment and long-term outcome. All data will be entered in an Excel database.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All IEM adult patients who were transitioned from the pediatric clinic to the adult metabolic clinic (the Centre for Molecular Disease in Lausanne and the Division of Endocrinology, Diabetology, Hypertension and Nutrition of the HUG) since its creation in 2013 and those who were referred to our clinic for suspicion of IEM and requiring further investigation.

Exclusion criteria

  • Age < 16 years . Any document attesting a refusal to participate will exclude the data entry of the concerned patient.

Treatment and study plan

Primary outcomes

  1. Specific diagnosis of IEM listed by their frequency

    Time frame: First visit

    Clinical outcome

  2. Age at diagnosis (years/months)

    Time frame: First visit

    Clinical outcome

  3. Medical complications

    Time frame: 4 years

    Clinical outcome including acute liver failure, nephropathy, metabolic acidosis, ophthalmologic anomalies, epilepsy, encephalopathy, myopathy, neuropathy, diabetes

  4. Specific treatment for Inborn Errors of Metabolism

    Time frame: 4 years

    Treatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, carnitine, ubiquinone, vitamins, specific diet, dialysis, specific metabolic formula

  5. Number of hospital admission

    Time frame: 4 years

    Clinical outcome

  6. Survival rate (%)

    Time frame: 4 years

    Clinical Outcome

  7. Gender (Male/female)

    Time frame: First visit

    Demography outcome

Secondary outcomes

  1. Abdominal Ultrasound results

    Time frame: 4 years

    Radiological Imaging description of spleen and/or liver when available (size, echostructure)

  2. Magnetic resonance Imaging scan

    Time frame: 4 years

    Radiological Imaging description of brain, abdomen and bone when available

  3. Bone density test

    Time frame: 4 years

    Radiological Imaging description of bone including T-score when available

  4. Biological biomarkers of specific diseases (lysosomal storage disorders and galactosemia)

    Time frame: 4 years

    Laboratory including blood concentration of chitotriosidase and Galactose-1-Phosphate

  5. Clinical chemistry

    Time frame: 4 years

    Laboratory including blood concentration of sodium, potassium, liver function tests, creatinine, uric acid, urea, amino acids, acylcarnitine profile, methylmalonate, total homocysteine and urine concentration of organic acids

  6. Hematology tests

    Time frame: 4 years

    Laboratory (blood count, international normalized ratio, prothrombin time)

  7. Enzyme activity in leucocytes and/or fibroblasts

    Time frame: 4 years

    Enzyme activity of deficient enzyme when available for lysosomal storage diseases, mucopolysaccharidoses, cobalamin deficiency, diseases, classical homocystinuria

  8. Molecular analysis results of candidate gene for Inborn Errors of metabolism

    Time frame: 4 years

    Laboratory including mutation results confirming the molecular origin of the disease when available

Other outcomes

  1. Educational level

    Time frame: 4 years

    Demography outcome

  2. Profession

    Time frame: 4 years

    Demography outcome

Sponsors and collaborators

Lead sponsor

University of Lausanne

Other

Registry information

Official study title

Clinical Characteristics of Adult Patients With Inborn Errors of Metabolism in French-speaking Switzerland

Important dates

Study start
2018
Primary completion
2019
Study completion
2020
First posted
May 23, 2018
Registry last updated
Jul 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.